AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17470687 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy alone
Number of subjects: 0
Study 15127068 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly used food models
Number of subjects: 50
Study 15127068 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger-sized food models
Number of subjects: 50
Study 12905875 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune enhanced enteral nutrition (arginine, RNA, omega 3 fatty acid enriched)
Number of subjects: 120
Study 9630386 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (0.9 g total catechins)
Number of subjects: 12
Study 9630386 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (0.3 g total catechins)
Number of subjects: 12
Study 9630386 — intervention group
Group type: COMPARATOR
Intervention: Black tea with milk (100 ml in 600 ml)
Number of subjects: 12
Study 7835196 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops
Number of subjects: 46
Study 7835196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3135784 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) at 120% of resting energy expenditure (REE) with 0.2 g of N/kg/d
Number of subjects: 16
Study 3135784 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) at 200% of resting energy expenditure (REE) with 0.33 g of N/kg/d
Number of subjects: 16
Study 31394274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu-based conditioning (Flu1: Flu 120-150 mg/m2, Cy 120-200 mg/kg, ATG 20 mg/kg; Flu2: Flu 150 mg/m2, Cy 300 mg/m2, ATG 20 mg/kg)
Number of subjects: 147
Study 31394274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu1 conditioning
Number of subjects: 147
Study 31394274 — intervention group
Group type: COMPARATOR
Intervention: Flu2 conditioning
Number of subjects: 147
Study 31394274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu-based conditioning
Number of subjects: 147
Study 28754566 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) levels
Number of subjects: 46
Study 28754566 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FFR <0.90
Number of subjects: 46
Study 28754566 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ADMA
Number of subjects: 46
Study 28754566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized ADMA (≥0.60 µM)
Number of subjects: 46
Study 28754566 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA
Number of subjects: 46
Study 25050594 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/F‐HFA 100/6 μg pMDI
Number of subjects: 95
Study 25050594 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol 320/9 μg DPI
Number of subjects: 95
Study 25050594 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone/salmeterol 500/50 μg DPI
Number of subjects: 95
Study 22210797 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification program using GPS vehicle tracking devices with contingency incentives and disincentives
Number of subjects: 6
Study 22210797 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (no treatment)
Number of subjects: 6
Study 21350421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 78
Study 21350421 — intervention group
Group type: COMPARATOR
Intervention: Milgamma
Number of subjects: 78
Study 19228428 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg, qid)
Number of subjects: 109
Study 19228428 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (30 mg once daily) plus inhaled formoterol (9 microg bid)
Number of subjects: 109
Study 16402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (n=15) infusion for 72 hours
Number of subjects: 29
Study 16402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (n=14) infusion for 72 hours
Number of subjects: 29
Study 16402915 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term inotropic support (Milrinone or Dobutamine)
Number of subjects: 29
Study 16402915 — intervention group
Group type: COMPARATOR
Intervention: Patients with decompensated CHF before inotropic treatment
Number of subjects: 29
Study 16402915 — intervention group
Group type: COMPARATOR
Intervention: Age-matched healthy volunteers (n=15, 54.1±3.2 years)
Number of subjects: 29
Study 15673102 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhydrin (MH)
Number of subjects: 7
Study 15673102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7
Study 12498742 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of pleasant images
Number of subjects: 16
Study 12498742 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of unpleasant images
Number of subjects: 16
Study 12498742 — intervention group
Group type: COMPARATOR
Intervention: Neutral images (control)
Number of subjects: 16
Study 9619473 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentionally directed away from complaints during acquisition
Number of subjects: 56
Study 9619473 — intervention group
Group type: COMPARATOR
Intervention: Not attentionally directed away from complaints during acquisition
Number of subjects: 56
Study 8702068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator treatment for an average of 18.7 months
Number of subjects: 60
Study 2716625 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of salbutamol (Glaxo)
Number of subjects: 21
Study 2716625 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of salbutamol sulphate (Riker)
Number of subjects: 21
Study 2716625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2716625 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of salbutamol
Number of subjects: 21
Study 2716625 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of salbutamol sulphate
Number of subjects: 21
Study 1233531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage of perphenacine
Number of subjects: 20
Study 1233531 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 31169924 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET; high-intensity interval training plus power training)
Number of subjects: 29
Study 31169924 — intervention group
Group type: COMPARATOR
Intervention: Control (CT; usual care)
Number of subjects: 29
Study 27511956 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling of choice in taking on care responsibilities
Number of subjects: 1087
Study 27511956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged caregiving and limited availability of accessible and affordable care services
Number of subjects: 1087
Study 25443473 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Cystic Fibrosis Questionnaire‐‐Revised (CFQ‐R)
Number of subjects: 314
Study 25443473 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Burden scale
Number of subjects: 314
Study 23136195 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg) plus mitoxantrone and prednisone (MP)
Number of subjects: 144
Study 23136195 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (7.5 mg/kg) plus mitoxantrone and prednisone (MP)
Number of subjects: 144
Study 23136195 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) plus mitoxantrone and prednisone (MP)
Number of subjects: 144
Study 23136195 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg) and (7.5 mg/kg)
Number of subjects: 144
Study 21756757 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + DDI + NVP
Number of subjects: 198
Study 21756757 — intervention group
Group type: EXPERIMENTAL
Intervention: D4T + 3TC + NVP
Number of subjects: 198
Study 21756757 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + 3TC + NVP
Number of subjects: 198
Study 21756757 — intervention group
Group type: EXPERIMENTAL
Intervention: D4T or DDI
Number of subjects: 198
Study 21756757 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-containing regimen
Number of subjects: 198
Study 19469601 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET)
Number of subjects: 40
Study 19469601 — intervention group
Group type: COMPARATOR
Intervention: Supportive Group Therapy (SGT)
Number of subjects: 40
Study 16908789 — intervention group
Group type: COMPARATOR
Intervention: Varenicline 1.0 mg twice daily
Number of subjects: 518
Study 16908789 — intervention group
Group type: COMPARATOR
Intervention: Varenicline 0.5 mg twice daily
Number of subjects: 518
Study 16908789 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (both doses)
Number of subjects: 518
Study 15204455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental verbal contingencies for stuttering
Number of subjects: 38
Study 15204455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent severity ratings
Number of subjects: 38
Study 11759177 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid liposomes (Liposom Forte) administered intramuscularly (2 ml every other day for 60 days)
Number of subjects: 64
Study 11759177 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid liposomes (Liposom Forte) administered intramuscularly
Number of subjects: 64
Study 11759177 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intramuscularly
Number of subjects: 64
Study 9160017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 129
Study 9160017 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pars plana vitrectomy
Number of subjects: 129
Study 9160017 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap-biopsy
Number of subjects: 129
Study 9160017 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vitrectomy
Number of subjects: 129
Study 9160017 — intervention group
Group type: COMPARATOR
Intervention: Factors other than treatment
Number of subjects: 129
Study 8195354 — intervention group
Group type: EXPERIMENTAL
Intervention: Superovulation with pure follicle stimulating hormone (FSH)
Number of subjects: 224
Study 8195354 — intervention group
Group type: COMPARATOR
Intervention: Control group (56 patients matched for age, category, and duration of infertility)
Number of subjects: 224
Study 3073903 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocomponent human insulin
Number of subjects: 138
Study 3073903 — intervention group
Group type: COMPARATOR
Intervention: Monocomponent porcine insulin
Number of subjects: 138
Study 3073903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 138
Study 29939959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis plus standard care
Number of subjects: 62
Study 29939959 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Group
Number of subjects: 62
Study 28716454 — intervention group
Group type: COMPARATOR
Intervention: 2D mammography
Number of subjects: 1227
Study 28716454 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D plus DBT
Number of subjects: 1227
Study 25457116 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklists
Number of subjects: 48
Study 23132825 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided HF care
Number of subjects: 151
Study 23132825 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) management
Number of subjects: 151
Study 21146930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 177
Study 21146930 — intervention group
Group type: COMPARATOR
Intervention: Active control procedure
Number of subjects: 177
Study 21146930 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 177
Study 18496949 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery
Number of subjects: 10
Study 18496949 — intervention group
Group type: COMPARATOR
Intervention: No EC‐IC bypass surgery
Number of subjects: 10
Study 16458316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/day niacin
Number of subjects: 30
Study 16458316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12934974 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (N = 18)
Number of subjects: 44
Study 12934974 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol decanoate (N = 26)
Number of subjects: 44
Study 11123486 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg maximum daily dose, given three times a day)
Number of subjects: 62
Study 11123486 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.8 mg maximum daily dose, given three times a day)
Number of subjects: 62
Study 11123486 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 62
Study 11123486 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 62
Study 9387732 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection Salviae Miltiorrhizae
Number of subjects: 53
Study 9387732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 53
Study 1329920 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg
Number of subjects: 0
Study 1329920 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 7500 I.U.
Number of subjects: 0
Study 1329920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Enoxaparin and UF heparin
Number of subjects: 0
Study 1329920 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed post-operative DVT
Number of subjects: 0
Study 3883817 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 51
Study 3883817 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 51
Study 3883817 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine and Amitriptyline
Number of subjects: 51
Study 30428503 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with follow-up calls at home for 12 weeks
Number of subjects: 62
Study 30428503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training or follow-up calls)
Number of subjects: 62
Study 30428503 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with follow-up calls at home
Number of subjects: 62
Study 30121453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus all-trans retinoic acid (ATRA)
Number of subjects: 0
Study 30121453 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 26756766 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative supervised exercise for 6 weeks
Number of subjects: 124
Study 26756766 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 124
Study 23980693 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interruption of sedatives (stopped daily and restarted when COMFORT-behavior score ≥17)
Number of subjects: 30
Study 23980693 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interruption of sedatives
Number of subjects: 30
Study 23980693 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study 21812937 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined theory‐based interactive postpartum sexual health education program (IPSHEP)
Number of subjects: 250
Study 21812937 — intervention group
Group type: COMPARATOR
Intervention: Interactive, self‐help pamphlet
Number of subjects: 250
Study 21812937 — intervention group
Group type: COMPARATOR
Intervention: Routine education (10-15 minute educational talk and sexual health pamphlet)
Number of subjects: 250
Study 20078813 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 50
Study 20078813 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 50
Study 18029971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (5-FU, adriamycin, and poly A:U)
Number of subjects: 292
Study 18029971 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (5-FU and adriamycin)
Number of subjects: 292
Study 16294263 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 or 5 mg daily for up to 3 years
Number of subjects: 3979
Study 16294263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3979
Study 12131600 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (maximum of 150 mg/day)
Number of subjects: 28
Study 12131600 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 28
Study 11696473 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients
Number of subjects: 38
Study 11696473 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 38
Study 9136270 — intervention group
Group type: EXPERIMENTAL
Intervention: Object-centered (OC) task
Number of subjects: 12
Study 9136270 — intervention group
Group type: COMPARATOR
Intervention: Trajectory-centered (TC) task
Number of subjects: 12
Study 8052812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin/metronidazole
Number of subjects: 488
Study 8052812 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline/metronidazole
Number of subjects: 488
Study 2947149 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg, three tablets daily for two weeks)
Number of subjects: 54
Study 2947149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three tablets daily for two weeks)
Number of subjects: 54
Study 29482596 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 200
Study 29482596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 200
Study 29482596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Haloperidol and Ketamine
Number of subjects: 200
Study 29482596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 27232884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib plus gefitinib
Number of subjects: 38
Study 27232884 — intervention group
Group type: COMPARATOR
Intervention: Cediranib plus placebo
Number of subjects: 38
Study 26230563 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program in Depressive disorders integrated with Mindful Practice
Number of subjects: 56
Study 23997107 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 49
Study 23997107 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smokers
Number of subjects: 49
Study 23997107 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 49
Study 23997107 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 49
Study 20371737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 16
Study 18509576 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocapnic hyperpnoea training
Number of subjects: 14
Study 17154780 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-cm-diameter disk at a distance of 18 cm
Number of subjects: 0
Study 17154780 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm disk at 50 cm
Number of subjects: 0
Study 17154780 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel physical size object
Number of subjects: 0
Study 17154780 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar physical size object
Number of subjects: 0
Study 12662365 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to reduce dietary fat only
Number of subjects: 25
Study 12662365 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to reduce dietary fat and sugar
Number of subjects: 25
Study 10905596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (3 MU/thrice weekly of alpha-IFN and 1000-1200 mg/daily of ribavirin)
Number of subjects: 100
Study 10905596 — intervention group
Group type: COMPARATOR
Intervention: Alpha-IFN alone (3 MU/thrice weekly)
Number of subjects: 100
Study 8935140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 30
Study 8935140 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 30
Study 8935140 — intervention group
Group type: EXPERIMENTAL
Intervention: Codanthrusate
Number of subjects: 30
Study 8935140 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of stimulant and softening laxatives
Number of subjects: 30
Study 1408620 — intervention group
Group type: EXPERIMENTAL
Intervention: High contextual interference (random practice)
Number of subjects: 52
Study 1408620 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice (low interference)
Number of subjects: 52
Study 1408620 — intervention group
Group type: COMPARATOR
Intervention: Serial practice
Number of subjects: 52
Study 1408620 — intervention group
Group type: COMPARATOR
Intervention: Serial with high interference practice
Number of subjects: 52
Study 31899111 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 13
Study 31899111 — intervention group
Group type: COMPARATOR
Intervention: No Kinesio Taping (No KT)
Number of subjects: 13
Study 29293367 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard subcutaneous basal‐bolus insulin and blinded CGM (group 1)
Number of subjects: 16
Study 29293367 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump and blinded CGM (group 2)
Number of subjects: 16
Study 29293367 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump and nonblinded CGM (group 3)
Number of subjects: 16
Study 29293367 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (CGM)
Number of subjects: 16
Study 29293367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (insulin pump and nonblinded CGM)
Number of subjects: 16
Study 27573531 — intervention group
Group type: EXPERIMENTAL
Intervention: Video clips of patients describing their colposcopy
Number of subjects: 88
Study 27573531 — intervention group
Group type: COMPARATOR
Intervention: Clinician describing the procedure
Number of subjects: 88
Study 25903251 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity risk feedback
Number of subjects: 147
Study 25903251 — intervention group
Group type: COMPARATOR
Intervention: No obesity risk feedback (Control)
Number of subjects: 147
Study 25903251 — intervention group
Group type: EXPERIMENTAL
Intervention: Choosing fewer unhealthful foods
Number of subjects: 147
Study 22990758 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing twice a day (6 breaths/minute for 15 minutes)
Number of subjects: 92